News

As part of the collaboration, the companies will carry out an observational study in chronic metabolic disease patients as well as those with increased risk of complications like

As part of the collaboration, both the companies will conduct research and preclinical development activities together for identifying new monovalent small molecules which regulate target proteins via stabilisation,

An investigational T-cell redirecting bispecific antibody, Talquetamab targets GPRC5D, a new multiple myeloma cells target, and CD3, a component of the T-cell receptor. The bispecific antibody is indicated

As part of the collaboration, the companies will co-develop Bifunctional HER2-Sialidase, which is currently in preclinical development stage, and a second bifunctional sialidase that is to be developed

The regulator has approved the therapy as a potential new standard of care to treat Pompe disease, a rare, progressive and severe muscle disorder. Individuals with this disease

Rinvoq, which is discovered and developed by AbbVie scientists, is a selective JAK inhibitor that is being studied in many immune-mediated inflammatory diseases. The regulator has recommended the

A fully human biologic, Cosentyx has been developed to directly inhibit interleukin-17A (IL-17A), a cytokine. The regulatory approval is granted for the use of the therapy, either alone

The vaccine candidate seeks to prevent anthrax in people after suspected or confirmed exposure to Bacillus anthracis. AV7909 is being assessed in adult persons between 18 and 65

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose